Log In
Print
BCIQ
Print
Print this Print this
 

Aloxi, Onicit, Paloxi, palonosetron

  Manage Alerts
Collapse Summary General Information
Company Helsinn Healthcare S.A.
DescriptionSelective serotonin (5-HT3) receptor antagonist
Molecular Target Serotonin (5-HT3) receptor
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationEmesis
Indication DetailsPrevent acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy in patients ages 1 month to <17 years; Prevent chemotherapy-induced nausea and vomiting (CINV); Prevent chemotherapy-induced nausea and vomiting (CINV) in pediatric patients; Prevent post-operative nausea and vomiting (PONV); Treat chemotherapy-induced nausea and vomiting (CINV)
Regulatory Designation

U.S. - Undisclosed Review (Prevent chemotherapy-induced nausea and vomiting (CINV) in pediatric patients)

Partner

Eisai Co. Ltd.; Lee's Pharmaceutical Holdings Ltd.; Taiho Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today